Inner Mongolia Furui Medical Science Co., Ltd. Class A

Inner Mongolia Furui Medical Science Co., Ltd. Class A

SSZSE:300049
40.33
CNY
-1.48
(-3.54%)
1.19EPS
70.56P/E
12.44BMarket Cap
Apr 29Next Earn
Inner Mongolia Furui Medical Science Co., Ltd. Class A
SZSE:300049
(Shenzhen Stock Exchange)

Recent

price

40.33

P/E

ratio

70.56

div

yld

0.19%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.85
1.21
1.64
2.13
5.18
2.31
3.14
3.1
3.18
3.25
3.15
3.46
3.83
4.39
5.12
6.01
6.21
Revenue per Share
0.19
0.21
0.16
0.02
0.7
0.35
0.46
0.23
0.13
0.17
0.24
0.37
0.37
0.39
0.43
0.58
0.67
Basic EPS, GAAP
0.04
0.14
0.25
-0.85
-0.26
0.12
-0.25
0.35
-0.06
0.74
0.35
0.55
0.38
0.44
0.01
0.61
- -
Free Cash Flow per Basic Share
0.1
0.07
0.16
0.01
0.03
0.11
0.11
0.12
0.11
0.01
0.01
0.01
0.27
0.2
0.01
0.01
0.08
Dividend per Share
2.75
2.81
2.83
2.85
3.22
5.09
5.56
5.68
5.07
5.01
5.14
5.78
5.87
5.88
6.56
7.47
7.54
Book Value per Share
2.71
2.19
2.09
2.09
2.15
3.98
4.31
3.91
3.26
2.83
2.98
3.68
3.77
3.69
3.7
4.59
4.62
Tangible Book Value per Share
247
249
249
245
125
262
263
266
272
256
256
260
263
263
263
266
264
Basic Weighted Avg Shares
210
302
408
523
646
604
827
823
867
832
808
898
1,009
1,154
1,349
1,595
1,636
Sales/Revenue/Turnover
27.92
22.94
12.82
3.96
19.63
19.69
21.28
18.79
15.59
16.52
18.08
19.67
18.37
21
22.89
25.03
25.59
Operating Margin (%)
8
10
11
16
41
22
35
46
44
51
69
67
72
81
91
101
- -
Depreciation Expense
47
52
41
5
87
92
121
61
35
43
62
95
98
102
113
154
176
Net Income, GAAP
24.21
22.59
24.27
88.2
30.39
18.44
20.74
47.17
61.11
20.94
20.81
21.73
24.12
24.76
27.6
26.28
24.98
Effective Tax Rate (%)
22.28
17.36
10.09
0.94
13.51
15.17
14.64
7.42
4.08
5.22
7.67
10.63
9.7
8.8
8.4
9.66
10.76
Profit Margin (%)
595
419
420
310
414
1,085
1,025
1,018
645
702
743
870
994
956
1,154
1,062
1,075
Working Capital
1
8
9
6
- -
- -
- -
10
9
69
55
54
42
45
55
69
112
LT Debt
687
703
734
749
915
1,651
1,825
1,916
1,514
1,552
1,616
1,806
1,826
1,847
2,128
2,472
2,530
Total Equity
10.24
7.51
4.88
0.25
9.4
7.13
7.99
3.74
2.67
6.14
5.52
7.99
7.59
10
9.77
11.2
12.84
Return on Invested Capital (%)
10.14
7.16
5.94
1.01
10.11
6.59
5.27
2.74
1.53
-0.68
2.12
2.45
2.72
1.41
1.59
2.15
1.67
Return on Capital (%)
11.09
7.53
5.83
0.69
11.26
8.43
8.64
4.13
2.5
3.27
4.64
6.65
6.39
6.57
6.88
8.27
9.22
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
103
132
131
LT Borrowings
10
44
45
LT Finance Leases
70
73
67
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
265
264
264
Market Capitalization
15,342
10,264
12,437

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,519
1,487
1,511
Cash, Cash Equivalents & STI
749
738
740
Accounts Receivable, Net
389
359
400
Inventories
150
146
152
Total Current Liabilities
442
469
436
Payables & Accruals
- -
- -
- -
ST Debt
103
132
131
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.66%
9.08%
16.15%
Free Cash Flow
446.29%
1,300.31%
6,555.08%
Net Income, GAAP
11.37%
21.61%
36.02%
Sales/Revenue/Turnover
10.79%
14.62%
18.26%
Total Cash Common Dividend
334.45%
680.28%
3.87%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
323
320
337
369
1,349
2025
330
383
- -
494
1,595
2026
360
395
387
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.12
0.1
0.04
0.43
2025
0.11
0.09
- -
0.16
0.58
2026
0.12
0.12
0.27
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.15
-0.15
0.01
2025
- -
- -
- -
-0.08
0.01
2026
- -
- -
0.15
- -
- -
Business
Inner Mongolia Furui Medical Science Co., Ltd. (300049.SZ) engages in the research, development, production, and sale of pharmaceuticals, diagnostic equipment, and medical services focused on liver disease prevention, diagnosis, and treatment in China and internationally; its core products and services include Compound Turtle and Soft Liver Tablets for hepatology treatment, the FibroScan series of liver fibrosis diagnostic instruments, digital health management platforms, prescription drugs, and health management center services targeting chronic liver conditions such as fibrosis, hepatitis, and fatty liver disease. The company operates through two primary segments, pharmaceutical production and sales alongside diagnostic equipment research, development, production, and sales, with subsidiaries and operations extending to France, the United States, Germany, Spain, the United Kingdom, Italy, Singapore, Hong Kong, and other regions; founded in 1998 and headquartered in Beijing, China, it lists on the Shenzhen Stock Exchange GEM and maintains a workforce of approximately 867 employees serving hospitals, clinics, and patients globally. In recent developments, the company pursues strategic expansion through an equity acquisition framework agreement to acquire a 96.20% stake in Chengdu Furuihui Hospital Management Co., enhancing its medical services capabilities, while continuing partnerships with healthcare institutions and emphasizing digital transformation and international compliance certifications like ISO 13485 and CE marking amid steady revenue growth from equipment and pharmaceutical divisions.